Cipla Limited (NSE:CIPLA)
India
· Delayed Price · Currency is INR 1,522.50
+10.90 (0.72%)
May 13, 2025, 3:29 PM IST
Cipla Revenue
In the fiscal year ending March 31, 2025, Cipla had annual revenue of 284.09B INR with 11.25% growth. Cipla had revenue of 70.19B in the quarter ending March 31, 2025, with 13.72% growth.
Revenue
284.09B
Revenue Growth
+11.25%
P/S Ratio
4.57
Revenue / Employee
9.62M
Employees
27,764
Market Cap
1,220.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 284.09B | 28.73B | 11.25% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
| Fortis Healthcare | 75.61B |
Cipla News
- 25 days ago - Cipla’s Goa unit gets ‘Voluntary Action Indicated’ classification from USFDA after inspection - Business Upturn
- 4 weeks ago - Cipla in focus after USFDA approves generic version of blockbuster cancer drug Abraxane - Business Upturn
- 4 weeks ago - Cipla receives USFDA approval for Generic Abraxane - Business Upturn
- 4 weeks ago - Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’ - Business Upturn
- 5 weeks ago - Cipla: Business Model, Q3 FY25 Earnings, Promoter Details, and Shareholding Pattern - Business Upturn
- 5 weeks ago - Nifty 50 top losers today, April 4: Tata Steel, Hindalco Industries, ONGC, Tata Motors, Cipla and more - Business Upturn
- 5 weeks ago - Cipla shares drop over 6% after Trump hints at pharma tariffs; heavy U.S. exposure adds pressure - Business Upturn
- 5 weeks ago - Nifty 50 top gainers today, April 3: Power Grid, Sun Pharmaceutical, Cipla, UltraTech and more - Business Upturn